425 related articles for article (PubMed ID: 27462372)
1. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes.
Jojima T; Tomotsune T; Iijima T; Akimoto K; Suzuki K; Aso Y
Diabetol Metab Syndr; 2016; 8():45. PubMed ID: 27462372
[TBL] [Abstract][Full Text] [Related]
2. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
[TBL] [Abstract][Full Text] [Related]
3. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
Kern M; Klöting N; Mark M; Mayoux E; Klein T; Blüher M
Metabolism; 2016 Feb; 65(2):114-23. PubMed ID: 26773934
[TBL] [Abstract][Full Text] [Related]
4. Combination of APD668, a G protein-coupled receptor 119 agonist with linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in a murine model of non-alcoholic steatohepatitis with diabetes.
Bahirat UA; Talwar R; Shenoy RR; Nemmani KVS; Goel RN
Med Mol Morphol; 2019 Mar; 52(1):36-43. PubMed ID: 29959534
[TBL] [Abstract][Full Text] [Related]
5. SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in
Korbut AI; Taskaeva IS; Bgatova NP; Muraleva NA; Orlov NB; Dashkin MV; Khotskina AS; Zavyalov EL; Konenkov VI; Klein T; Klimontov VV
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340263
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice.
Takahashi H; Nomiyama T; Terawaki Y; Horikawa T; Kawanami T; Hamaguchi Y; Tanaka T; Motonaga R; Fukuda T; Tanabe M; Yanase T
Biochem Biophys Rep; 2019 Jul; 18():100640. PubMed ID: 31032431
[TBL] [Abstract][Full Text] [Related]
7. Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis.
Klein T; Fujii M; Sandel J; Shibazaki Y; Wakamatsu K; Mark M; Yoneyama H
Med Mol Morphol; 2014 Sep; 47(3):137-49. PubMed ID: 24048504
[TBL] [Abstract][Full Text] [Related]
8. Co-administration of APD668, a G protein-coupled receptor 119 agonist and linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in mice fed on a high trans-fat diet.
Bahirat UA; Shenoy RR; Talwar R; Goel RN; Nemmani KVS
Biochem Biophys Res Commun; 2018 Jan; 495(2):1608-1613. PubMed ID: 29203247
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis.
Chun HJ; Kim ER; Lee M; Choi DH; Kim SH; Shin E; Kim JH; Cho JW; Han DH; Cha BS; Lee YH
Metabolism; 2023 Aug; 145():155612. PubMed ID: 37277060
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of SGLT2 and DPP-4 promotes natriuresis and improves glomerular hemodynamic abnormalities in KK/Ta-Ins2
Fujita H; Otomo H; Takahashi Y; Yamada Y
Biochem Biophys Res Commun; 2022 Dec; 635():84-91. PubMed ID: 36265286
[TBL] [Abstract][Full Text] [Related]
12. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
Aronson R
Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
Kim ES; Deeks ED
Drugs; 2015 Sep; 75(13):1547-57. PubMed ID: 26323340
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.
Jain RK
Expert Opin Pharmacother; 2017 Apr; 18(6):545-549. PubMed ID: 28375658
[TBL] [Abstract][Full Text] [Related]
15. Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice.
Fushimi Y; Obata A; Sanada J; Nogami Y; Ikeda T; Yamasaki Y; Obata Y; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
Sci Rep; 2021 Aug; 11(1):16120. PubMed ID: 34373487
[TBL] [Abstract][Full Text] [Related]
16. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.
Chen L; Klein T; Leung PS
Curr Mol Med; 2012 Sep; 12(8):995-1004. PubMed ID: 22804249
[TBL] [Abstract][Full Text] [Related]
17. Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH.
Hupa-Breier KL; Dywicki J; Hartleben B; Wellhöner F; Heidrich B; Taubert R; Mederacke YE; Lieber M; Iordanidis K; Manns MP; Wedemeyer H; Hardtke-Wolenski M; Jaeckel E
Biomedicines; 2021 Mar; 9(4):. PubMed ID: 33808404
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.
Tan X; Hu J
Ann Endocrinol (Paris); 2016 Oct; 77(5):557-562. PubMed ID: 27062036
[TBL] [Abstract][Full Text] [Related]
19. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus.
Qiang S; Nakatsu Y; Seno Y; Fujishiro M; Sakoda H; Kushiyama A; Mori K; Matsunaga Y; Yamamotoya T; Kamata H; Asano T
Diabetol Metab Syndr; 2015; 7():104. PubMed ID: 26594248
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.
Rizos CV; Filippatos TD; Elisaf MS
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):117-125. PubMed ID: 29241374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
